glycogen phosphorylase (gp)

AVE5688, an inhibitor of glycogen phosphorylase (GP), has IC50 values of 430 nM and 915 nM, and Kd values of 170 nM and 530 nM for rmGPb and rmGPa, respectively. It is suitable for research on type 2 diabetes.

Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.

Uric acid is an important antioxidant that scavenges oxygen radicals and reactive oxygen species (such as singlet oxygen and peroxynitrite), inhibits lipid peroxidation, helps maintain stable blood pressure, and is the final product of purine metabolism. It is commonly used to induce hypertension models.

N6-Methyladenosine 5'-monophosphate disodium salt is a glycogen phosphorylase b activator and an inhibitor of adenylate kinase II.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.

Ingliforib (CP 368296) is a novel glycogen phosphorylase inhibitor with antihyperglycemic and cardioprotective properties.

CP-320626 is a highly efficient human liver glycogen phosphorylase (GP) inhibitor with cholesterol-lowering activity. It inhibits cholesterol biosynthesis by directly inhibiting CYP51 and can be used in type 2 diabetes research.